Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Ann Oncol. 2012 Sep;23 Suppl 10:x101-3. doi: 10.1093/annonc/mds308.
Today, melanoma is considered as a spectrum of melanocytic malignancies that can be characterized by clinical and molecular features, including targetable mutations in several kinases. The successful development of therapies, targeting mutated BRaF (v-raf murine sarcoma viral oncogene homolog B1) or c-KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog), has resulted in new treatment options including vemurafenib, imatinib and mitogen-activated protein kinase inhibitors. These molecules are selected if the respective mutation is present. after this first progress in the treatment of advanced melanoma, there is expectation that combinations of kinase inhibitor will additionally improve the overall survival rates and progression-free survival in advanced melanoma.
如今，黑色素瘤被认为是一类具有不同临床和分子特征的黑素细胞恶性肿瘤，包括几种激酶的可靶向突变。针对突变型 BRAF（v-raf 鼠肉瘤病毒癌基因同源物 B1）或 c-KIT（v-kit 哈迪-祖克曼 4 猫肉瘤病毒癌基因同源物）的治疗方法的成功开发，为新的治疗选择提供了可能，包括维莫非尼、伊马替尼和丝裂原活化蛋白激酶抑制剂。如果存在相应的突变，就会选择这些分子。在晚期黑色素瘤治疗取得这一初步进展后，人们期望激酶抑制剂联合使用将进一步提高晚期黑色素瘤的总生存率和无进展生存率。
